To include your compound in the COVID-19 Resource Center, submit it here.

Array reports lead-in Phase III data for binimetinib and encorafenib in mCRC

Array BioPharma Inc. (NASDAQ:ARRY) reported data from the safety lead-in portion of the Phase III BEACON CRC trial showing that binimetinib (MEK162) plus encorafenib (LGX818) and Erbitux cetuximab led to a confirmed overall response rate (ORR) of 41%, including 1

Read the full 408 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE